VVOS

Vivos Therapeutics, Inc. (VVOS) Risks & Opportunities Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 2.8 (Weak)

Severe liquidity strain, with a 0.21 current ratio versus better-capitalized peers, raises refinancing and dilution risk if operating cash needs persist.

Negative interest coverage and subscale leverage metrics leave VVOS more exposed than larger telehealth peers to higher funding costs and tighter capital access.

A very weak cash-conversion profile, driven by long receivables and stretched payables, signals working-capital pressure that peers with stronger collections can absorb more easily.

Limited financial flexibility increases vulnerability to demand softness or reimbursement delays, while peers with stronger balance sheets can sustain investment through volatility.

Opportunities

Score:

If VVOS stabilizes liquidity, its low-debt profile versus leveraged peers could preserve optionality for growth initiatives without the same balance-sheet drag.

The negative cash-conversion cycle suggests working-capital release potential, which could improve near-term funding capacity faster than peers with less favorable payables dynamics.

Overall Score

Score:

VVOS is constrained primarily by acute liquidity and coverage pressure versus peers, while only limited upside exists from balance-sheet optionality and working-capital improvement.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Vivos Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →